ClinicalTrials.gg
CompletedNCT01655381Updated Jan 31, 2017Results posted

A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-31.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
101st of 110
15 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
62nd of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 101st largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 62nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who have completed the 104-week WA19926 core study. Eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, >/= 18 years of age
  • Participants who complete their last WA19926 core study visit (Week 104) and who may benefit from study drug treatment, at baseline or later if they are in remission DAS28 at Week 104 of WA19926, according to the Investigator's assessment
  • No current or recent adverse event or laboratory finding preventing the use of the study drug dose of tocilizumab 8 mg/kg at baseline visit
  • Women of must agree to use adequate as defined by protocol during and up to 3 months after treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant females
  • Participants who have withdrawn prematurely from the WA19926 core study for any reason
  • Treatment with any agent or cell-depleting therapies since the last administration of study drug in WA19926
  • Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL) 1 agent, or a T-cell costimulation modulator since the last administration of study drug in WA19926
  • Immunization with a live/attenuated vaccine since the last administration of study drug in WA19926
  • Diagnosis since last WA19926 visit (Week 104) of rheumatic disease other than rheumatoid arthritis
  • Diagnosis since last WA19926 visit (Week 104) of inflammatory joint disease other than rheumatoid arthritis
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, including tocilizumab and its
  • Evidence of severe uncontrolled concomitant disease or disorder
  • Known active or history of recurrent infections
  • Active tuberculosis requiring treatment in the previous 3 years
  • History of alcohol, drug or chemical abuse since inclusion in the WA19926 study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.

    Drug: Tocilizumab

Interventions

  • Tocilizumab 8 mg/kg administered intravenously.

    Also known as: RoActemra®, Actemra®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Any Adverse Event (AE)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any AE that is fatal; life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect in a neonate/infant or significant medical event in the Investigator's judgment. AE of special interest (AESI) includes serious and/or medically significant infectious; myocardial infarction(MI) / acute coronary syndrome (ACS); gastrointestinal (GI) perforation; anaphylaxis / hypersensitivity reactions; demyelinating disorders; stroke; serious and/or medically significant bleeding events; serious and/or medically significant hepatic events; malignancies malignant.

    Time frame: Up to 160 weeks

Secondary outcomes

  1. Percentage of Participants With at Least One Clinical Remission Period

    Clinical remission: Disease Activity Score Based on 28-joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) less than (\<)2.6 and/or Simplified Disease Activity Index (SDAI) less than or equal to (≤)3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0-10, with higher scores corresponding to greater disease activity. SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0-86, where lower scores indicate less disease activity.

    Time frame: Up to approximately 148 weeks

  2. Percentage of Participants With at Least One Drug-Free Period

    Drug-free remission period was defined as clinical remission for at least 2 consecutive assessment visits (every 12 weeks) AND without tocilizumab administration during this clinical remission period.

    Time frame: Up to approximately 148 weeks

  3. Cumulative Time of Remission Per Participant Over the Extension Study Period

    Clinical remission was defined as DAS28-ESR \<2.6 and/or SDAI ≤3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity. SDAI scores range from 0 to 86, where lower scores indicate less disease activity.

    Time frame: Up to approximately 148 weeks

  4. Percentage of Participants With at Least 1 Rheumatoid Arthritis (RA) Flare

    An RA flare was defined as an increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.

    Time frame: Up to approximately 148 weeks

  5. Time to RA Flare Following Remission or Drug-Free Remission

    Time to RA flare was defined as period of clinical remission or drug-free remission followed by flare of DAS28-ESR (increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2). In the case of several remission periods for the same participant, the largest period was used.

    Time frame: Up to approximately 148 weeks

  6. Change From Day 1 in DAS28-ESR Scores Over Time

    DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  7. Change From Day 1 in Simplified Disease Activity Index (SDAI) Scores Over Time

    SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), and the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0 to 86, where lower scores indicate less disease activity.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  8. Change From Day 1 in Tender Joint Count Based on 28 Joints (TJC28) Over Time

    The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 tender joints. Higher scores correspond to greater disease activity.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  9. Change From Day 1 in Swollen Joint Count Based on 28 Joints (SJC28) Over Time

    The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 swollen joints. Higher scores correspond to greater disease activity.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  10. Erythrocyte Sedimentation Rate (ESR) Over Time

    ESR is an direct measure of how much inflammation is in the body. The normal range is 0-22 mm/hour for men and 0-29 mm/hour for women. Higher scores correspond to greater disease activity.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  11. C-reactive Protein (CRP) Level

    C-reactive protein (CRP) is a blood test marker for inflammation in the body. Normal CRP levels are below 5 milligrams per liter (mg/L). Higher scores correspond to greater disease activity.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  12. Participants' Global Assessment of Pain (VAS) Score

    The participants' global assessment of pain (VAS) was assessed using a 100-mm horizontal VAS with 0=no pain to 100=maximum pain.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  13. Participants' Global Assessment of Disease Activity (VAS) Score

    The participants' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  14. Physicians' Global Assessment of Disease Activity (VAS) Score

    The physicians' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.

    Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

  15. Percentage of Participants With Health Assessment Questionnaire Disability Index (HAQ-DI) Remission

    HAQ-DI remission was defined as HAQ-DI score \<0.5. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128 140

  16. Percentage of Participants With Clinically Meaningful Improvement From Baseline in HAQ-DI

    Clinically meaningful improvement was defined as an improvement in HAQ-DI score of ≥0.22. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140

07

Results

Posted Jan 31, 2017

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started15
Completed12
Not completed3
Withdrew: Investigator decision1
Withdrew: Moved to another city1
Withdrew: Insufficient treatment response1

Outcome measures

PrimaryPercentage of Participants With Any Adverse Event (AE)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any AE that is fatal; life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect in a neonate/infant or significant medical event in the Investigator's judgment. AE of special interest (AESI) includes serious and/or medically significant infectious; myocardial infarction(MI) / acute coronary syndrome (ACS); gastrointestinal (GI) perforation; anaphylaxis / hypersensitivity reactions; demyelinating disorders; stroke; serious and/or medically significant bleeding events; serious and/or medically significant hepatic events; malignancies malignant.

Time frame:
Up to 160 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Any Adverse Event (AE)
percentage of participantsTocilizumab
AE93.3
SAE6.7
Non-serious AE93.3
Tocilizumab-related AE80.0
Tocilizumab-related SAE0
Tocilizumab-related non-SAE80.0
AESI20.0
Tocilizumab-related AESI20.0
AE leading to dose modification33.3
AE leading to Tocilizumab discontinuation6.7
AE leading to death0
SecondaryPercentage of Participants With at Least One Clinical Remission Period

Clinical remission: Disease Activity Score Based on 28-joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) less than (\<)2.6 and/or Simplified Disease Activity Index (SDAI) less than or equal to (≤)3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0-10, with higher scores corresponding to greater disease activity. SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0-86, where lower scores indicate less disease activity.

Time frame:
Up to approximately 148 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Clinical Remission Period
percentage of participantsTocilizumab
Percentage of Participants With at Least One Clinical Remission Period100.0
SecondaryPercentage of Participants With at Least One Drug-Free Period

Drug-free remission period was defined as clinical remission for at least 2 consecutive assessment visits (every 12 weeks) AND without tocilizumab administration during this clinical remission period.

Time frame:
Up to approximately 148 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Drug-Free Period
percentage of participantsTocilizumab
Percentage of Participants With at Least One Drug-Free Period13.3
SecondaryCumulative Time of Remission Per Participant Over the Extension Study Period

Clinical remission was defined as DAS28-ESR \<2.6 and/or SDAI ≤3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity. SDAI scores range from 0 to 86, where lower scores indicate less disease activity.

Time frame:
Up to approximately 148 weeks
Reported as:
Median · days
Cumulative Time of Remission Per Participant Over the Extension Study Period
daysTocilizumab
Cumulative Time of Remission Per Participant Over the Extension Study Period598.00 (179.0 to 1,072.0)
SecondaryPercentage of Participants With at Least 1 Rheumatoid Arthritis (RA) Flare

An RA flare was defined as an increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.

Time frame:
Up to approximately 148 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Rheumatoid Arthritis (RA) Flare
percentage of participantsTocilizumab
Percentage of Participants With at Least 1 Rheumatoid Arthritis (RA) Flare40.0
SecondaryTime to RA Flare Following Remission or Drug-Free Remission

Time to RA flare was defined as period of clinical remission or drug-free remission followed by flare of DAS28-ESR (increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2). In the case of several remission periods for the same participant, the largest period was used.

Time frame:
Up to approximately 148 weeks
Reported as:
Median · days
Time to RA Flare Following Remission or Drug-Free Remission
daysTocilizumab
Time to RA Flare Following Remission or Drug-Free Remission289.0 (179.0 to 739.0)
SecondaryChange From Day 1 in DAS28-ESR Scores Over Time

DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Mean · units on a scale
Change From Day 1 in DAS28-ESR Scores Over Time
units on a scaleTocilizumab
Day 1 (n = 14)2.09 ± 1.12
Change at Week 12 (n = 10)-0.43 ± 0.96
Change at Week 24 (n = 13)-0.65 ± 1.86
Change at Week 36 (n = 11)-0.03 ± 1.42
Change at Week 48 (n = 13)-0.58 ± 1.46
Change at Week 56 (n = 11)-1.02 ± 1.50
Change at Week 68 (n = 11)-1.39 ± 1.31
Change at Week 80 (n = 10)-0.83 ± 1.33
Change at Week 92 (n = 10)-0.69 ± 1.50
Change at Week 104 (n = 10)-0.94 ± 1.44
Change at Week 116 (n = 6)-1.15 ± 1.37
Change at Week 128 (n = 2)0.40 ± 1.70
Change at Week 140 (n = 1)0.10 ± NA
SecondaryChange From Day 1 in Simplified Disease Activity Index (SDAI) Scores Over Time

SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), and the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0 to 86, where lower scores indicate less disease activity.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Mean · units on a scale
Change From Day 1 in Simplified Disease Activity Index (SDAI) Scores Over Time
units on a scaleTocilizumab
Day 1 (n = 6)4.40 ± 3.67
Change at Week 12 (n = 6)-1.70 ± 3.43
Change at Week 24 (n = 42.68 ± 17.12
Change at Week 36 (n = 0)NA ± NA
Change at Week 48 (n = 3)-3.70 ± 3.21
Change at Week 56 (n = 3)-2.90 ± 1.64
Change at Week 68 (n = 2)-7.30 ± 3.54
Change at Week 80 (n = 3)-3.37 ± 3.42
Change at Week 92 (n = 4)-2.05 ± 5.11
Change at Week 104 (n = 2)-6.10 ± 0.14
Change at Week 116 (n = 3)-4.77 ± 2.46
Change at Week 128 (n = 0)NA ± NA
Change at Week 140 (n = 1)-0.90 ± NA
SecondaryChange From Day 1 in Tender Joint Count Based on 28 Joints (TJC28) Over Time

The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 tender joints. Higher scores correspond to greater disease activity.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Mean · tender joints
Change From Day 1 in Tender Joint Count Based on 28 Joints (TJC28) Over Time
tender jointsTocilizumab
Day 1 (n = 15)2.07 ± 5.62
Change at Week 12 (n = 15)-0.87 ± 6.58
Change at Week 24 (n = 14)0.29 ± 9.22
Change at Week 36 (n = 14)1.00 ± 8.68
Change at Week 48 (n = 14)1.07 ± 9.24
Change at Week 56 (n = 13)-1.77 ± 6.26
Change at Week 68 (n = 12)-1.42 ± 5.92
Change at Week 80 (n = 11)-2.45 ± 6.67
Change at Week 92 (n = 12)-0.67 ± 3.75
Change at Week 104 (n = 11)-1.82 ± 7.05
Change at Week 116 (n = 6)-1.00 ± 0.89
Change at Week 128 (n = 3)0.67 ± 2.08
Change at Week 140 (n = 1)-1.00 ± NA
SecondaryChange From Day 1 in Swollen Joint Count Based on 28 Joints (SJC28) Over Time

The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 swollen joints. Higher scores correspond to greater disease activity.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Mean · swollen joints
Change From Day 1 in Swollen Joint Count Based on 28 Joints (SJC28) Over Time
swollen jointsTocilizumab
Day 1 (n = 15)0.33 ± 0.62
Change at Week 12 (n = 15)0.27 ± 1.44
Change at Week 24 (n = 14)0.50 ± 2.03
Change at Week 36 (n = 14)1.50 ± 2.71
Chnage at Week 48 (n = 14)0.29 ± 1.38
Change at Week 56 (n = 13)0.46 ± 2.07
Change at Week 68 (n = 12)-0.08 ± 1.16
Change at Week 80 (n = 11)0.09 ± 1.38
Change at Week 92 (n = 12)0.50 ± 2.35
Change at Week 104 (n = 11)0.55 ± 1.86
Change at Week 116 (n = 6)-0.17 ± 1.72
Change at Week 128 (n = 3)0.00 ± 0.00
Change at Week 140 (n = 1)0.00 ± NA
SecondaryErythrocyte Sedimentation Rate (ESR) Over Time

ESR is an direct measure of how much inflammation is in the body. The normal range is 0-22 mm/hour for men and 0-29 mm/hour for women. Higher scores correspond to greater disease activity.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Median · mm/hour
Erythrocyte Sedimentation Rate (ESR) Over Time
mm/hourTocilizumab
Day 1 (n = 14)10.0 (1.0 to 61.0)
Week 12 (n = 11)2.00 (1.0 to 20.0)
Week 24 (n = 14)2.50 (1.0 to 24.0)
Week 36 (n = 12)2.00 (1.0 to 26.0)
Week 48 (n = 14)2.00 (1.0 to 19.0)
Week 56 (n = 13)2.00 (1.0 to 9.0)
Week 68 (n = 12)2.50 (1.0 to 13.0)
Week 80 (n = 11)3.00 (2.0 to 6.0)
Week 92 (n = 11)2.00 (1.0 to 20.0)
Week 104 (n = 11)2.00 (1.0 to 30.0)
Week 116 (n= 6)2.00 (2.0 to 15.0)
Week 128 (n= 3)3.00 (2.0 to 4.0)
Week 140 (n= 1)10.00 (10.0 to 10.0)
SecondaryC-reactive Protein (CRP) Level

C-reactive protein (CRP) is a blood test marker for inflammation in the body. Normal CRP levels are below 5 milligrams per liter (mg/L). Higher scores correspond to greater disease activity.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Median · mg/L
C-reactive Protein (CRP) Level
mg/LTocilizumab
Day 1 (n = 6)4.70 (0.5 to 24.0)
Week 12 (n = 11)2.00 (0.3 to 10.0)
Week 24 (n = 11)2.00 (0.2 to 9.0)
Week 36 (n = 6)0.85 (0.3 to 2.0)
Week 48 (n = 8)1.30 (0.2 to 5.0)
Week 56 (n = 9)2.00 (0.2 to 21.0)
Week 68 (n = 7)2.00 (0.5 to 12.0)
Week 80 (n = 8)2.00 (0.3 to 10.7)
Week 92 (n = 8)2.00 (0.3 to 25.0)
Week 104 (n = 7)2.00 (0.3 to 22.5)
Week 116 (n= 4)2.00 (2.0 to 3.0)
Week 128 (n= 1)2.00 (2.0 to 2.0)
Week 140 (n= 1)4.00 (4.0 to 4.0)
SecondaryParticipants' Global Assessment of Pain (VAS) Score

The participants' global assessment of pain (VAS) was assessed using a 100-mm horizontal VAS with 0=no pain to 100=maximum pain.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Median · units on a scale
Participants' Global Assessment of Pain (VAS) Score
units on a scaleTocilizumab
Day 1 (n = 15)11.00 (0.0 to 50.0)
Week 12 (n = 15)7.00 (0.0 to 37.0)
Week 24 (n = 14)9.00 (0.0 to 75.0)
Week 36 (n = 14)10.00 (0.0 to 66.0)
Week 48 (n = 14)8.00 (0.0 to 64.0)
Week 56 (n = 13)4.00 (0.0 to 50.0)
Week 68 (n = 12)4.00 (0.0 to 25.0)
Week 80 (n = 11)19.00 (1.0 to 40.0)
Week 92 (n = 12)8.50 (0.0 to 50.0)
Week 104 (n = 11)9.00 (0.0 to 24.0)
Week 116 (n= 6)3.50 (0.0 to 20.0)
Week 128 (n= 3)3.00 (1.0 to 20.0)
Week 140 (n= 1)6.00 (6.0 to 6.0)
SecondaryParticipants' Global Assessment of Disease Activity (VAS) Score

The participants' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Median · units on a scale
Participants' Global Assessment of Disease Activity (VAS) Score
units on a scaleTocilizumab
Day 1 (n = 15)13.00 (0.0 to 30.0)
Week 12 (n = 15)17.00 (0.0 to 75.0)
Week 24 (n = 14)18.50 (0.0 to 80.0)
Week 36 (n = 14)10.00 (0.0 to 68.0)
Week 48 (n = 14)7.50 (0.0 to 49.0)
Week 56 (n = 13)5.00 (0.0 to 50.0)
Week 68 (n = 12)5.00 (0.0 to 32.0)
Week 80 (n = 11)24.00 (1.0 to 70.0)
Week 92 (n = 12)10.50 (0.0 to 30.0)
Week 104 (n = 11)10.00 (0.0 to 57.0)
Week 116 (n= 6)4.00 (0.0 to 15.0)
Week 128 (n= 3)7.00 (2.0 to 10.0)
Week 140 (n= 1)15.00 (15.0 to 15.0)
SecondaryPhysicians' Global Assessment of Disease Activity (VAS) Score

The physicians' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.

Time frame:
Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Median · units on a scale
Physicians' Global Assessment of Disease Activity (VAS) Score
units on a scaleTocilizumab
Day 1 (n = 15)5.00 (0.0 to 20.0)
Week 12 (n = 15)6.00 (0.0 to 21.0)
Week 24 (n = 13)1.00 (0.0 to 60.0)
Week 36 (n = 14)5.00 (0.0 to 55.0)
Week 48 (n = 14)5.00 (0.0 to 50.0)
Week 56 (n = 13)6.00 (0.0 to 60.0)
Week 68 (n = 12)4.50 (0.0 to 13.0)
Week 80 (n = 11)3.00 (0.0 to 18.0)
Week 92 (n = 12)9.0 (0.0 to 43.0)
Week 104 (n = 11)5.00 (0.0 to 40.0)
Week 116 (n= 6)5.00 (0.0 to 10.0)
Week 128 (n= 3)15.00 (1.0 to 30.0)
Week 140 (n= 1)5.00 (5.0 to 5.0)
SecondaryPercentage of Participants With Health Assessment Questionnaire Disability Index (HAQ-DI) Remission

HAQ-DI remission was defined as HAQ-DI score \<0.5. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128 140
Reported as:
Number · percentage of participants
Percentage of Participants With Health Assessment Questionnaire Disability Index (HAQ-DI) Remission
percentage of participantsTocilizumab
Baseline (n = 15)73.3
Week 12 (n = 9)66.7
Week 24 (n = 8)62.5
Week 36 (n = 10)60.0
Week 48 (n = 10)50.0
Week 56 (n = 10)60.0
Week 68 (n = 9)77.8
Week 80 (n = 9)66.7
Week 92 (n = 8)75.0
Week 104 (n = 7)71.4
Week 116 (n= 3)100
Week 128 (n= 1)100
Week 140 (n= 1)100
SecondaryPercentage of Participants With Clinically Meaningful Improvement From Baseline in HAQ-DI

Clinically meaningful improvement was defined as an improvement in HAQ-DI score of ≥0.22. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Meaningful Improvement From Baseline in HAQ-DI
percentage of participantsTocilizumab
Week 12 (n = 9)33.3
Week 24 (n = 8)25.0
Week 36 (n = 10)40.0
Week 48 (n = 10)30.0
Week 56 (n = 10)30.0
Week 68 (n = 9)33.3
Week 80 (n = 9)22.2
Week 92 (n = 8)12.5
Week 104 (n = 7)28.6
Week 116 (n= 3)100
Week 128 (n= 1)100
Week 140 (n= 1)100

Adverse events

Collected over Up to 160 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—1/15 (6.7%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
Oedema peripheralGeneral disorders1/15
Most frequent other events
Showing 10 of 79
Most frequent other events
EventTocilizumab
BronchitisInfections and infestations6/15
Back painMusculoskeletal and connective tissue disorders5/15
GastroenteritisInfections and infestations4/15
NasopharyngitisInfections and infestations4/15
AstheniaGeneral disorders4/15
InsomniaPsychiatric disorders3/15
Oral herpesInfections and infestations2/15
PharyngitisInfections and infestations2/15
TracheitisInfections and infestations2/15
Urinary tract infectionInfections and infestations2/15

Baseline characteristics

Analysis was performed in Included population, defined as all participants who entered the study.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean54.8 ± 9.1
Gender
Gender(Participants)Tocilizumab
Female12
Male3
08

Study locations

6 sites
  • Cahors, 46005, France
  • Montpellier, 34295, France
  • Mulhouse, 68070, France
  • Orleans, 45032, France
  • Paris, 75651, France
  • Toulouse, 31059, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2012
First posted
Aug 1, 2012
Start
Apr 2012
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Jan 31, 2017
Last update
Jan 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01655381
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 1, 2012
Start date
Apr 2012
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Jan 31, 2017
Last update
Jan 31, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion